Vaccines for parasitic and bacterial diseases

Current Opinion in Immunology

Volumn 15, Issue 4, 2003, Pages 456-460

  Reed, Steven G ^a,b,c   Campos Neto, Antonio ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

ANIMAL MODEL; BACTERIAL INFECTION; CELL ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFECT; HUMAN; INFECTION PREVENTION; LEISHMANIA; LEISHMANIASIS; MALARIA; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PLASMODIUM FALCIPARUM; REGULATORY MECHANISM; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION;

EID: 0042405127     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(03)00069-4     Document Type: Review

References (31)

1. Lee E.A., Palmer D.R., Flanagan K.L., Reece W.H., Odhiambo K., Marsh K., Pinder M., Gravenor M.B., Keitel W.A., Kester K.E.et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun. 70:2002;1417-1421.
2. O'Donnell R.A., Koning-Ward T.F., Burt R.A., Bockarie M., Reeder J.C., Cowman A.F., Crabb B.S. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med. 193:2001;1403-1412.
3. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., Ballou W.R., Conway D.J., Reece W.H., Gothard P.et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial. Lancet. 358:2001;1927-1934.
4. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., Krzych U., Delchambre M., Voss G., Dowler M.G.et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 183:2001;640-647.
5. Birkett A., Lyons K., Schmidt A., Boyd D., Oliveira G.A., Siddique A., Nussenzweig R., Calvo-Calle J.M., Nardin E. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in pre-clinical analyses in rodent and primate hosts. Infect Immun. 70:2002;6860-6870.
6. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y.A., Reed S.G., Grimaldi G. Jr. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun. 69:2001;4103-4108.
7. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 70:2002;2828-2836.
8. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., Campos-Neto A., Reed S.G. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine. 20:2002;3292-3303.
9. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., Modabber F., Campos-Neto A., Reed S.G. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun. 70:2002;4215-4225 Using MPL®, a potent adjuvant acceptable for human use, a polyprotein consisting of three important leishmania antigens protected highly susceptible Balb/c mice with as little as 2μg protein.
10. Badaro R., Lobo I., Nakatani M., Muinos A., Netto E.M., Coler R.N., Reed S.G. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis. 5:2001;223-232.
11. Borges M.M., Campos-Neto A., Sleath P., Grabstein K.H., Morrissey P.J., Skeiky Y.A., Reed S.G. Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein. Infect Immun. 69:2001;5270-5277.
12. Valenzuela J.G., Belkaid Y., Garfield M.K., Mendez S., Kamhawi S., Rowton E.D., Sacks D.L., Ribeiro J.M. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med. 194:2001;331-342.
13. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. J Exp Med. 194:2001;F7-F9.
14. Behar S.M., Dascher C.C., Grusby M.J., Wang C.R., Brenner M.B. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med. 189:1999;1973-1980.
15. + T cells. J Exp Med. 196:2002;1473-1481.
16. Sambandamurthy V.K., Wang X., Chen B., Russell R.G., Derrick S., Collins F.M., Morris S.L., Jacobs W.R. Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med. 8:2002;1171-1174.
17. Hondalus M.K., Bardarov S., Russell R., Chan J., Jacobs W.R. Jr., Bloom B.R. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun. 68:2000;2888-2898.
18. Jackson M., Phalen S.W., Lagranderie M., Ensergueix D., Chavarot P., Marchal G., McMurray D.N., Gicquel B., Guilhot C. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun. 67:1999;2867-2873.
19. Smith D.A., Parish T., Stoker N.G., Bancroft G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun. 69:2001;1142-1150.
20. + T cell responses and protection against Leishmania major infection. J Exp Med. 195:2002;1565-1573.
21. Gierynska M., Kumaraguru U., Eo S.K., Lee S., Krieg A., Rouse B.T. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol. 76:2002;6568-6576.
22. Weinrich O.A., van Pinxteren L.A., Meng O.L., Birk R.P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun. 69:2001;2773-2778.
23. Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YAW: Prospects for a better vaccine against tuberculosis. Tuberculosis 2003, in press. [Au: do you have any further details of this paper yet?].
24. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., Giuliani M.M., Masignani V., Santini L., Savino S.et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 195:2002;1445-1454 This paper describes an interesting cell-surface protein in N. meningitidis, which is present in 52 out of 53 virulent strains of the bacteria. This molecule induces strong bactericidal and protective antibodies in infant rat model of the infection, thus suggesting that this protein may be a novel vaccine candidate to control meningococcal diseases.
25. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., Boyd A.P., Sollner J., Schmidt W., von Ahsen U.et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA. 99:2002;6573-6578 This paper describes a rapid and efficient antigen discovery strategy for the identification and cloning of genes encoding microbial cell surface proteins. Such an approach is a major advance in the development of vaccines against extracellular microorganisms.
26. Tettelin H., Nelson K.E., Paulsen I.T., Eisen J.A., Read T.D., Peterson S., Heidelberg J., DeBoy R.T., Haft D.H., Dodson R.J.et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 293:2001;498-506.
27. Parkhill J., Achtman M., James K.D., Bentley S.D., Churcher C., Klee S.R., Morelli G., Basham D., Brown D., Chillingworth T.et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature. 404:2000;502-506.
28. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., Ketchum K.A., Hood D.W., Peden J.F., Dodson R.J.et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 287:2000;1809-1815.
29. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., Griffiths K.E., Marchal G., Leclerc C., Cole S.T. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 9:2003;533-539.
30. Bao L., Chen W., Zhang H., Wang X. Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis Bacillus Calmette-Guerin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun. 71:2003;1656-1661.
31. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 71:2003;1672-1679.